HTA decisions are the scientific gatekeeper for market access, providing the payer-negotiated insights necessary for pricing, coverage, and commercial success.
These reviews are resource-intensive. When fragmented or delayed, companies can lose crucial market access windows and the ability to proactively influence future appraisals.
Biolevate bridges this gap by enabling teams to scale HTA reviews without compromising accuracy, ensuring a full and defensible rationale at every step.
16× faster decision reviews
Review HTA decisions faster by automating retrieval, screening, structured extraction, and first-pass appraisal rationale analysis.
2,000+ decisions benchmarked/year
Scale HTA benchmarking across agencies, indications, comparators, endpoints, and appraisal contexts with expert-defined extraction logic.
Reusable rationale library
Build a source-linked library of agency rationales, restrictions, uncertainty drivers, evidence gaps, and value arguments reusable across markets and indications.
How it works
1
Retrieve and filter past HTA decisions — pull decisions from internal repositories and public sources (e.g., NICE, G-BA, HAS, CADTH) to build a complete, searchable corpus.
2
Define a screening rationale — select a critical subset (same indication/comparator/endpoints/setting) and let Biolevate scale the criteria across the corpus to produce a curated, review-ready set.
3
Extract arguments and evidence patterns — capture key decision drivers (comparators, endpoints, uncertainty, subgroups, cost-effectiveness, RWE expectations) into structured tables with traceable sources.
4
Generate dossier-ready rationales — produce the first version of your argumentation and evidence story using your templates, grounded in extracted data and linked to decision sources for validation.
Reusable decision base: a structured, searchable library of HTA decisions and rationales reusable across indications and markets.
Defensible outputs: source-linked claims with a run record to support internal review and payer-facing credibility.